Navigation Links
New Program Developed in the Fight Against Feline Aids
Date:11/4/2009

LTCI NOW is created by Imulan to inform cat owners about fast, new treatment program for FIV and FELV

New York, N.Y. (PRWEB) November 4, 2009 -- IMULAN BioTherapeutics, LLC has developed the LTCI NOW program in an effort to educate cat owners about the new, fast way to get LTCI for feline immunodeficiency virus (FIV) and feline leukemia virus (FeLV). Like Human Immunodeficiency Virus (HIV), FIV and FeLV are retroviral infections that can cause immunosuppression.

The LTCI NOW program will not only inform pet owners about the first and only USDA-conditionally approved treatment for FIV and FeLV, but also provide a truly simple and fast way to either obtain the pioneered product through their current veterinarian or through a network of current LTCI-using veterinarians across the country (Imulan’s ‘Treatment Network’) . LTCI’s sole focus is to make things as easy as possible on the pet owner; all they need to do is go to the website, and provide their veterinarian with the LTCI NOW brochure – the vet takes it from there. LTCI, or Lymphocyte T-Cell Immunomodulator, is only available through veterinarians, and is a major step forward in combating these highly serious and potentially fatal feline illnesses, which can lead to severe immune suppression (like HIV), anemia, and increased risk of other infections. In addition to fostering awareness about the feline illnesses and treatment with LTCI, IMULAN’s veterinarians will also offer free case consultations with the pet owner’s veterinarian.

According to Dr. Craig Woods, CEO of IMULAN, "IMULAN's LTCI NOW program is designed to make the process of getting LTCI for cats infected with FeLV and FIV as easy as possible. IMULAN has streamlined the process because time is of the essence for many of these patients, who often are very sick. FeLV and FIV remain devastating diseases, and the more veterinarians and owners are aware of the available options, the more effective our profession will be at managing these diseases.”

The LTCI NOW Program was established to further the awareness of these feline diseases. The goal for the program is to make the process as simple as possible for pet owners, allowing them easy access to information LTCI so they are informed in discussions with their veterinarian.

IMULAN BioTherapeutics, LLC is a privately held bioscience company, working to develop immune-based treatments for various life threatening animal diseases. With technologies that are able to modulate cells that coordinate immune response and inflammation, IMULAN is a leader in developing first-in-class technologies for veterinary medicine. LTCI, approved by the United States Department of Agriculture, is IMULAN’s first commercial product manufactured by T-Cyte Therapeutics, Inc. LTCI has received a conditional license from the United States Department of Agriculture, additional efficacy and potency studies are underway.

###

Read the full story at http://www.prweb.com/releases/2009/11/prweb3148704.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
2. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
3. SemBioSys updates Apo AI development program
4. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
5. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
8. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
9. Celebrity Designer Ty Pennington to Host ADHD Experts on Call Program
10. Diageo Sponsors Medical Society of the State of New Yorks Physicians Training Program
11. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Program Developed in the Fight Against Feline Aids
(Date:5/22/2017)... ... 2017 , ... Cancer diagnostics and pathology workflow solution provider ... Association for Pathology Informatics Annual Summit at the Wyndham Grand Hotel ... Diagnostic Cockpit and Consultation Portal, Inspirata will present research it led to help ...
(Date:5/19/2017)... , ... May 19, 2017 , ... In response to ... gait disorders, Biodex Medical Systems, Inc. announces the release of their Gait Trainer 3 ... been joined with a biomedical system to aid in rehabilitating individuals with cerebral palsy, ...
(Date:5/18/2017)... ... May 18, 2017 , ... Lajollacooks4u has added ... is a two-hour team-building package designed for groups of 10-30 people. Guests ... which include items, such as Blackened Shrimp with Edamame Salad, Pizza Rolls with ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... its scientific power by providing investigators access to a high-profile scientific advisory ... the scientific advisory board. “We are committed to offering superior services and ...
Breaking Biology Technology:
(Date:4/11/2017)... DUBLIN , Apr. 11, 2017 Research ... Tracking Market 2017-2021" report to their offering. ... The global eye tracking market to grow at ... The report, Global Eye Tracking Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):